Skip to main content

Table 3 Changes in biomarker levels from baseline to 12-weeks on treatment

From: Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases

 

Difference all patients

p-value

Difference treatment group 1

Difference treatment group 2

p-value

N

 

23

 

10

13

 

CTx ng/L

Median (IQR)

83 (2, 155)

<0.001

17 (−27, 83)

131 (79, 171)

0.034

BSAP IU/L

Median (IQR)

1 (0, 4)

0.011

0 (−1, 1)

3 (2, 5)

0.010

TGF-β, ng/ml

Median (IQR)

0.8 (−2.1, 4.9)

0.28

−0.1 (−2.1, 2.2)

2.4 (−0.0, 4.9)

0.41

Activin-A, pg/ml

Median (IQR)

111 (28, 526)

0.001

96 (−29, 596)

122 (34, 256)

0.60

NTx 2nM BCE/mM creatine

Median (IQR)

42 (−48, 168)

0.15

42 (−15, 179)

45 (−76, 108)

0.54

P1NP ng/ml

Median (IQR)

5742 (−6694, 19129)

0.24

1376 (−6694, 8498)

16539 (−1266, 21993)

0.26

BSP ng/ml

Median (IQR)

5.8 (−8.0, 9.5)

0.63

0.5 (−15.4, 6.4)

9.8 (0.8, 47.2)

0.14

FACT -BP

Median (IQR)

0 (−4, 3)

0.99

1 (0, 4)

−2 (−4, 1)

0.053

BPI

Median (IQR)

0 (−3, 4)

0.94

2 (0, 7)

−1 (−8, 1)

0.050